Key facts
- Bioworks’s last known valuation is $5.3M (Nov 2016).
- It has raised $60.5M; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include Saison Ventures, Lavender Hill Capital Partners, 18 Salisbury Capital, Cornell University, Goldwin Venture Partners — 13 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Bioworks
- ·The full record, as it builds
Funding rounds
No funding rounds for Bioworks are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bioworks
Developer of plant-derived material technology designed to create sustainable, eco-friendly alternatives for everyday products. The company offers next-generation plant-derived materials, expertise in brand development, OEM production capabilities, and customized materials for various applications, enabling manufacturers, designers, and product developers to create sustainable, eco-friendly products while supporting a circular and recycling-oriented economy.
- Sector
- Materials and Resources
- HQ
- Kyoto, Japan
- Founded
- 2015
- Employees
- 50
- Website
- bioworks.co.jp/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Bioworks doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bioworks shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bioworks in its N-PORT filings yet. We sweep new filings monthly.